{"abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cardiovascular and Renal Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.","action":"Notice; establishment of a public docket; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/09/06/2024-20062.html","cfr_references":[],"citation":"89 FR 72846","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The meeting will be held on October 10, 2024, from 8:15 a.m. to 5:30 p.m. Eastern Time.","disposition_notes":null,"docket_ids":["Docket No. FDA-2024-N-3969"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":80,"comment_start_date":"2024-09-06","updated_at":"2024-10-10T01:01:15.891-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2024-N-3969-0001","allow_late_comments":false,"id":"FDA-2024-N-3969-0001","comment_end_date":"2024-10-10","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2024-N-3969","title":"Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-- New Drug Application 215244 for Elamipretide Hydrochloride Injection"}],"document_number":"2024-20062","effective_on":null,"end_page":72847,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/09/06/2024-20062.xml","html_url":"https://www.federalregister.gov/documents/2024/09/06/2024-20062/cardiovascular-and-renal-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-docket","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-20062?publication_date=2024-09-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-09-06/2024-20062/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":176,"last_updated":"2026-04-04 16:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20062.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-20062.pdf?1725540333","publication_date":"2024-09-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/09/06/2024-20062.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":80,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2024-N-3969","supporting_documents_count":0,"docket_id":"FDA-2024-N-3969","document_id":"FDA-2024-N-3969-0001","regulation_id_number":null,"title":"Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-- New Drug Application 215244 for Elamipretide Hydrochloride Injection","checked_regulationsdotgov_at":"2024-10-11T01:00:11Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":72846,"subtype":null,"title":"Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection","toc_doc":"Cardiovascular and Renal Drugs Advisory Committee","toc_subject":"Hearings, Meetings, Proceedings, etc.:\n","topics":[],"type":"Notice","volume":89}